Rationally designed viruses for use as vaccines or solid tumor therapies

Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies. Both programs rely on scalable, low-cost manufacturing.

Safe and effective live-attenuated vaccines, presenting all target antigens

Target customized oncolytics to treat primary tumors and shrink off-site metastases

177,000

RSV hospitalizations among adults 65+ no vaccine

48.8 million

Flu cases in 2017-18, current vaccines <37% effective

1 in 8

US women (about 12%) will develop invasive breast cancer during lifetime.

Our breakthrough approach to live-attenuated virus design

1. Recode

2. Synthesize

3. Transfect

4. Recover

  • September 27, 2019

    Codagenix presenting at ID Week

    Come find Codagenix at ID Week, Oct 2-6 in Washington, DC. We are presenting two posters On Oct 5, describing our RSV and tetravalent Dengue vaccines: Poster #2764 : Generation of a Balanced, Tetravalent Dengue Vaccine Based on Contemporary Strains Using a Computational, Synthetic Biology-based Platform Poster #2777 : Synthetic Live-Attenuated Vaccine Against RSV is […]

    Full Story
  • August 27, 2019

    Codagenix Inc. Strengthens Leadership Team with Experienced Chief Medical Officer

    Farmingdale, New York, August 27, 2019– Codagenix, Inc. a synthetic biology-based vaccine and oncolytic company, today announced the appointment of Sybil Tasker, M.D., MPH, FACP, FIDSA as Chief Medical Officer. The goal of Codagenix is to bring rationally-designed, highly effective prophylactic vaccines and oncolytic virus therapies to the marketplace. “Codagenix has grown tremendously since our […]

    Full Story